Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement
Jun 19, 2013 ·
6m 48s
Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients...
show more
Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.
show less
Information
| Author | cancerGRACE |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
